Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Novavax shares slump as vaccine maker warns of its ability to stay in business

Published 03/01/2023, 07:01 AM
Updated 03/01/2023, 07:18 AM
© Reuters

© Reuters

By Scott Kanowsky 

Investing.com -- Shares in Novavax Inc (NASDAQ:NVAX) shed over a fourth of their value in pre-market U.S. trading on Wednesday after the COVID-19 vaccine maker warned of substantial doubt around its future in the wake of lower-than-expected fourth-quarter revenue.

The Maryland-based company flagged "significant uncertainty," particularly surrounding its 2023 sales, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi.

"[S]ubstantial doubt exists regarding our ability to continue as a going concern through one year from the date that these financial statements are issued," Novavax said in a statement.

A decision by the U.S. government not to extend an agreement with Novavax past December 2023 places $416 million at risk, according to a Reuters report. The result of the Gavi arbitration may also require the firm to refund about $700M it received from the group, the news agency said.

Novavax's quarterly top-line figure grew by 61% compared to the same period in the prior year, to $357M, but missed Bloomberg consensus estimates of $380.3M.

Meanwhile, expenses nearly doubled to $162M due to a strategy that will see Novavax move away from government contracts and attempt to start commercial sales of its COVID vaccine program. The business subsequently reported a net loss in the three months to the end of December of $182M, or $2.28 per share.

Analysts at Jefferies noted that while they continue to see value in Novavax's protein-based COVID jab, there are still a few uncertainties around the near-term outlook.

The slide in Novavax's shares put them on pace for their worst day in more than two months. The stock's market value had previously climbed to more than $20 billion at one point as it raced to develop a COVID vaccine, but has since slumped to less than $800M.

Latest comments

frick8ng scamdemic anyway
With “Died Suddenly” im sure demand is high.
Safe and effective.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.